These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 18461562

  • 1. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
    Thudi NK, Martin CK, Nadella MV, Fernandez SA, Werbeck JL, Pinzone JJ, Rosol TJ.
    Prostate; 2008 Jul 01; 68(10):1116-25. PubMed ID: 18461562
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model.
    Hung TT, Chan J, Russell PJ, Power CA.
    PLoS One; 2011 Jul 01; 6(5):e19389. PubMed ID: 21603655
    [Abstract] [Full Text] [Related]

  • 4. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
    Lee YP, Schwarz EM, Davies M, Jo M, Gates J, Zhang X, Wu J, Lieberman JR.
    Cancer Res; 2002 Oct 01; 62(19):5564-70. PubMed ID: 12359769
    [Abstract] [Full Text] [Related]

  • 5. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
    Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E.
    Prostate Cancer Prostatic Dis; 2005 Oct 01; 8(3):253-9. PubMed ID: 15999121
    [Abstract] [Full Text] [Related]

  • 6. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
    Szafran AA, Folks K, Warram J, Chanda D, Wang D, Zinn KR.
    Cancer Biol Ther; 2009 Jun 01; 8(12):1109-16. PubMed ID: 19652526
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
    Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P.
    J Natl Cancer Inst; 2007 Feb 21; 99(4):322-30. PubMed ID: 17312309
    [Abstract] [Full Text] [Related]

  • 8. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
    Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A.
    Clin Cancer Res; 2009 May 15; 15(10):3451-61. PubMed ID: 19401351
    [Abstract] [Full Text] [Related]

  • 9. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
    Mundy GR, Yoneda T, Hiraga T.
    Semin Oncol; 2001 Apr 15; 28(2 Suppl 6):35-44. PubMed ID: 11346863
    [Abstract] [Full Text] [Related]

  • 10. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J.
    Cancer Invest; 2002 Apr 15; 20 Suppl 2():45-54. PubMed ID: 12442349
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model.
    Böckelmann LC, Freytag V, Ahlers AK, Maar H, Gosau T, Baranowsky A, Schmitz R, Pantel K, Schumacher U, Haider MT, Lange T.
    Bone; 2023 Jun 15; 171():116741. PubMed ID: 36934984
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.
    Tsutsumi R, Hock C, Bechtold CD, Proulx ST, Bukata SV, Ito H, Awad HA, Nakamura T, O'Keefe RJ, Schwarz EM.
    J Orthop Res; 2008 Oct 15; 26(10):1340-6. PubMed ID: 18404739
    [Abstract] [Full Text] [Related]

  • 13. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
    Luo KW, Ko CH, Yue GG, Gao S, Lee JK, Li G, Fung KP, Leung PC, Evdokiou A, Lau CB.
    J Cancer Res Clin Oncol; 2015 Jun 15; 141(6):1025-36. PubMed ID: 25431338
    [Abstract] [Full Text] [Related]

  • 14. A single pretreatment by zoledronic acid converts metastases from osteolytic to osteoblastic in the rat.
    Nyangoga H, Blouin S, Libouban H, Baslé MF, Chappard D.
    Microsc Res Tech; 2010 Aug 15; 73(8):733-40. PubMed ID: 19953666
    [Abstract] [Full Text] [Related]

  • 15. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
    Odri G, Kim PP, Lamoureux F, Charrier C, Battaglia S, Amiaud J, Heymann D, Gouin F, Redini F.
    BMC Cancer; 2014 Mar 10; 14():169. PubMed ID: 24612486
    [Abstract] [Full Text] [Related]

  • 16. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
    Haider MT, Holen I, Dear TN, Hunter K, Brown HK.
    Bone; 2014 Sep 10; 66(100):240-50. PubMed ID: 24971713
    [Abstract] [Full Text] [Related]

  • 17. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
    Dedes PG, Kanakis I, Gialeli Ch, Theocharis AD, Tsegenidis T, Kletsas D, Tzanakakis GN, Karamanos NK.
    Biochim Biophys Acta; 2013 Jun 10; 1830(6):3625-34. PubMed ID: 23395844
    [Abstract] [Full Text] [Related]

  • 18. Fluorescence-guided surgery of prostate cancer bone metastasis.
    Miwa S, Matsumoto Y, Hiroshima Y, Yano S, Uehara F, Yamamoto M, Zhang Y, Kimura H, Hayashi K, Yamamoto N, Bouvet M, Sugimoto N, Tsuchiya H, Hoffman RM.
    J Surg Res; 2014 Nov 10; 192(1):124-33. PubMed ID: 24972740
    [Abstract] [Full Text] [Related]

  • 19. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
    Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL.
    Clin Cancer Res; 2003 Jan 10; 9(1):295-306. PubMed ID: 12538482
    [Abstract] [Full Text] [Related]

  • 20. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
    Peyruchaud O, Winding B, Pécheur I, Serre CM, Delmas P, Clézardin P.
    J Bone Miner Res; 2001 Nov 10; 16(11):2027-34. PubMed ID: 11697798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.